

**NSABP Protocol B-14: Characteristics of Patients
for whom Pathology Whole Section Material is Available for Study**

	Placebo	Tamoxifen	Registered	All
	No. (%)	No. (%)	No. (%)	No. (%)
Age				
<=49	133 (28.7)	121 (26.7)	162 (31.7)	416 (29.1)
50-59	146 (31.5)	137 (30.2)	122 (23.9)	405 (28.4)
>=60	184 (39.7)	196 (43.2)	227 (44.4)	607 (42.5)
Race				
White	424 (91.6)	423 (93.2)	471 (92.2)	1318 (92.3)
Black	18 (3.9)	18 (4.0)	22 (4.3)	58 (4.1)
Other	17 (3.7)	10 (2.2)	13 (2.5)	40 (2.8)
Unknown	4 (0.9)	3 (0.7)	5 (1.0)	12 (0.8)
Clinical Tumor Size (cm)				
<=2.0	255 (55.1)	258 (56.8)	347 (67.9)	860 (60.2)
2.1-4.0	184 (39.7)	166 (36.6)	145 (28.4)	495 (34.7)
>=4.1	24 (5.2)	30 (6.6)	19 (3.7)	73 (5.1)
Type of Surgery				
Mastectomy	261 (56.4)	264 (58.1)	322 (63.0)	847 (59.3)
Lumpectomy	202 (43.6)	190 (41.9)	189 (37.0)	581 (40.7)
Estrogen Receptor (fmol)				
10-49	189 (40.8)	183 (40.3)	208 (40.7)	580 (40.6)
50-99	100 (21.6)	92 (20.3)	114 (22.3)	306 (21.4)
100+	174 (37.6)	179 (39.4)	189 (37.0)	542 (38.0)
Disease-free Survival				
Alive, Event-free	154 (33.3)	202 (44.5)	263 (51.5)	619 (43.3)
Experienced an Event	309 (66.7)	252 (55.5)	248 (48.5)	809 (56.7)
Total Person Months of Follow-up for Events	63,400.3	72,304.2	80,430.7	216,135.2
Overall Survival				
Alive	243 (52.5)	268 (59.0)	342 (66.9)	853 (59.7)
Dead	220 (47.5)	186 (41.0)	169 (33.1)	575 (40.3)
Total Person Months of Follow-up for Deaths	82,682.0	85,280.3	91,629.2	259,591.5
All	463 (100.0)	454 (100.0)	511 (100.0)	1428 (100.0)